Jacob A Aelion

Oct 21, 2024 | ard.bmj.com | Laure Gossec |Laura Coates |Dafna D Gladman |Jacob A Aelion

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Aug 20, 2024 | ard.bmj.com | Laure Gossec |Laura Coates |Dafna D Gladman |Jacob A Aelion

DiscussionClinical trial data to support treatment guidelines for oligoarticular PsA are currently limited. FOREMOST is, to our knowledge, the first large, randomised, placebo-controlled trial only enrolling patients with oligoarticular PsA and provides valuable information on how patients with early disease and limited joint involvement respond to apremilast treatment.